SCHEDULE: Armistice Capital Reduces Aethlon Medical Stake Below 5%

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in Aethlon Medical Inc., a reduction that places their stake below the 5% threshold.

Summary

• Armistice Capital, LLC and Steven Boyd collectively hold beneficial ownership of 136,486 shares of Aethlon Medical Inc. common stock.
• This ownership represents 4.99% of the company's total outstanding common stock.
• The reporting persons, Armistice Capital, LLC and Steven Boyd, possess shared voting power and shared dispositive power over all 136,486 shares.
• This document is an Amendment No. 2 to a previous Schedule 13G filing, indicating a change in their beneficial ownership position.
• The shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital, LLC serving as its investment manager and Steven Boyd as the managing member of Armistice Capital.

Sentiment

Score: 4

Explanation: The reduction in beneficial ownership by a significant institutional investor, bringing their stake below the 5% threshold, is generally viewed negatively as it may signal reduced confidence or a strategic divestment.

Positives

• Armistice Capital, a recognized investment manager, maintains a significant, albeit reduced, stake in Aethlon Medical Inc.

Negatives

• The reduction in beneficial ownership below the 5% threshold by Armistice Capital and Steven Boyd could signal a decrease in investor conviction or a strategic portfolio adjustment.

Risks

• A reduction in a significant institutional investor's stake may be interpreted by the market as a negative signal regarding the company's future prospects or strategy.
• The market might react negatively to the news of a prominent investor reducing their position, potentially impacting share price.

Stakeholder Impact

• Shareholders may interpret the reduction in stake by a significant investor as a negative signal, potentially leading to downward pressure on the stock price.
• Management might face questions regarding the reasons for the investor's reduced position and its implications for future capital or strategic direction.

Key Dates

Recommendation

The reduction of Armistice Capital's beneficial ownership in Aethlon Medical Inc. to below 5% suggests a strategic divestment or a decrease in conviction by a sophisticated institutional investor. This move, especially as an amendment to a previous filing, often signals a less favorable outlook on the company's prospects, warranting a 'sell' recommendation for investors who follow institutional sentiment.

Keywords

Aethlon Medical, Armistice Capital, Steven Boyd, beneficial ownership, Schedule 13G, common stock, institutional investor, ownership change, SEC filing